[
  {
    "question": "Given that the patient is 67.3 years old, will the cancer have a recurrence in the next 12 months?\nA) Yes\nB) No",
    "answer": "B) No",
    "response": "B) No",
    "correct": true,
    "files_accessed": [
      "timeline0.txt",
      "specimen.txt"
    ],
    "files_hallucinated": [],
    "question_time": 93.22052597999573
  },
  {
    "question": "Given that the patient is 67.3 years old, will the cancer progress in the next 12 months?\nA) Yes\nB) No",
    "answer": "B) No",
    "response": "B) No",
    "correct": true,
    "files_accessed": [],
    "files_hallucinated": [],
    "question_time": 49.028547525405884
  },
  {
    "question": "Given that the patient is 69 years old, will the cancer have a recurrence in the next 6 months?\nA) Yes\nB) No",
    "answer": "A) Yes",
    "response": "A) Yes",
    "correct": true,
    "files_accessed": [
      "timeline1.txt"
    ],
    "files_hallucinated": [],
    "question_time": 60.4699981212616
  },
  {
    "question": "Given that the patient is 69 years old, will the cancer progress in the next 6 months?\nA) Yes\nB) No",
    "answer": "A) Yes",
    "response": "A) Yes",
    "correct": true,
    "files_accessed": [],
    "files_hallucinated": [],
    "question_time": 41.01087999343872
  },
  {
    "question": "Given that the patient is 69 years old, will the patient be still alive in the next 6 months?\nA) Yes\nB) No",
    "answer": "A) Yes",
    "response": "A) Yes",
    "correct": true,
    "files_accessed": [],
    "files_hallucinated": [],
    "question_time": 60.03354597091675
  },
  {
    "question": "Given that the patient is 69.9 years old, will the cancer progress in the next 6 months?\nA) Yes\nB) No",
    "answer": "A) Yes",
    "response": "A) Yes",
    "correct": true,
    "files_accessed": [
      "timeline2.txt"
    ],
    "files_hallucinated": [],
    "question_time": 63.38077211380005
  },
  {
    "question": "Given that the patient is 69.9 years old, will the patient be still alive in the next 6 months?\nA) Yes\nB) No",
    "answer": "B) No",
    "response": "B) No",
    "correct": true,
    "files_accessed": [],
    "files_hallucinated": [],
    "question_time": 38.68738031387329
  },
  {
    "conversation": [
      {
        "role": "system",
        "content": "You are a pathologist AI assistant expert at analyzing patient data and answering user questions.\nYou will be provided with files that you are allowed to read.\nTo ask for files, include in your reasoning [REQUEST: filename.extension] for each file you needExample: [REQUEST: image1.jpg] [REQUEST: image2.jpg]\nTo provide a final answer to a question, include [ANSWER: LETTER) your answer] in your response, specifying the answer choice you picked (A or B).\nYou MUST ONLY provide [ANSWER] when you have all necessary information.You also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history.\nExample: [PUBMED: search words]\n"
      },
      {
        "role": "user",
        "content": "You are given the following new patient information: \nThe patient is a 66.4-year-old White male with a diagnosis of colon adenocarcinoma. His clinical history includes detailed information on diagnosis, treatments, and lab tests spanning the period from age 66.4 to 67.3 years. A tumor sample from this patient has been sequenced, and mutation data is available to support further analysis and personalized treatment planning. The patient identifies as Non-Spanish, Non-Hispanic.\nNew files available:\n [FILE: specimen.txt]\n[FILE: timeline0.txt]Remember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history. If you ask for information, you must wait for the tool to provide it before continuing.\nExample: [PUBMED: search words]\n\n Question: Given that the patient is 67.3 years old, will the cancer have a recurrence in the next 12 months?\nA) Yes\nB) No\nRemember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history.\nExample: [PUBMED: search words]\n"
      },
      {
        "role": "assistant",
        "content": "Okay, I need to analyze the patient data to assess the likelihood of cancer recurrence within the next 12 months. To do this effectively, I need to review the provided files.\n\n[REQUEST: specimen.txt]\n[REQUEST: timeline0.txt]"
      },
      {
        "role": "user",
        "content": "[FILE: timeline0.txt] included in your context\nAGE: 66.409, diagnosis > performance_status --> ECOG: 4, \nAGE: 66.417, diagnosis > performance_status --> ECOG: 0, \nAGE: 66.450, surgery --> SUBTYPE: PROCEDURE, \nAGE: 66.450, diagnosis > cancer_presence --> HAS CANCER: No, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: No, PROCEDURE_TYPE: CT scan, PELVIS: No, OTHER: Yes, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: No, CHEST: No, \nAGE: 66.450, diagnosis > progression --> CT scan reveals cancer has NOT progressed.\nAGE: 66.450, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), CT, TUMOR_SITE: Lymph Nodes, PELVIS: No, OTHER: Yes, HEAD: No, ABDOMEN: No, CHEST: No, \nAGE: 66.814, samples > clinical_sample --> SAMPLE_ID: P-0043580-T01-IM6, PATIENT_ID: P-0043580, CANCER_TYPE: Colorectal Cancer, SAMPLE_TYPE: Primary, SAMPLE_CLASS: Tumor, METASTATIC_SITE: Not Applicable, PRIMARY_SITE: Ascending Colon, CANCER_TYPE_DETAILED: Colon Adenocarcinoma, GENE_PANEL: IMPACT468, SAMPLE_COVERAGE: 514, TUMOR_PURITY: 50.0, ONCOTREE_CODE: COAD, MSI_COMMENT: MICROSATELLITE STABLE (MSS). See MSI note below., MSI_SCORE: 0.0, MSI_TYPE: Stable, SOMATIC_STATUS: Matched, CLINICAL_GROUP_x: 3A, PATHOLOGICAL_GROUP: 2.0, CLINICAL_SUMMARY: Localized, ICD_O_HISTOLOGY_DESCRIPTION: Mucinous Adenocarcinoma, DIAGNOSIS_DESCRIPTION: Transverse Colon, TMB_NONSYNONYMOUS: 14.69986761, DX_DESCRIPTION: MUCINOUS ADENOCARCINOMA, EVENT_TYPE: Diagnosis, SUBTYPE: Primary, SOURCE: Tumor Registry, CLINICAL_GROUP_y: 3A, PATH_GROUP: 2A, STAGE_CDM_DERIVED: Stage 1-3, SUMMARY: Localized, ICD_10: C18.4, \nAGE: 66.814, surgery --> SUBTYPE: PROCEDURE, \nAGE: 66.814, diagnosis > diagnosis --> SUBTYPE: Primary, SOURCE: Tumor Registry, DX_DESCRIPTION: MUCINOUS ADENOCARCINOMA | TRANSVERSE COLON (M8480/3 | C184), CLINICAL_GROUP: 3A, PATH_GROUP: 2A, STAGE_CDM_DERIVED: Stage 1-3, SUMMARY: Localized, \nAGE: 66.875, diagnosis > cancer_presence --> HAS CANCER: Yes, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: Yes, PROCEDURE_TYPE: CT scan, PELVIS: Yes, OTHER: No, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 66.875, diagnosis > progression --> CT scan reveals cancer has NOT progressed.\nAGE: 66.875, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), CT, TUMOR_SITE: Lymph Nodes, PELVIS: Yes, OTHER: No, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 66.875, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), CT, TUMOR_SITE: Other, PELVIS: Yes, OTHER: No, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 66.875, labtest > cea_labs --> CEA: 10.0000 ng/ml          \nAGE: 66.910, surgery --> SUBTYPE: PROCEDURE, \nAGE: 66.910, specimen_surgery --> SAMPLE_ID: P-0043580-T01-IM6, SEQ_DATE: 0, \nAGE: 66.910, pathology > mmr --> SUBTYPE: MMR (IHC), MMR_ABSENT: False, \nAGE: 66.946, treatment > prior_meds --> SUBTYPE: Prior Medications to MSK, TREATMENT_TYPE: Medical Therapy, INFERRED_TX_PROB: 0.02, PRIOR_MED_TO_MSK: No prior medications, STYLE_COLOR: #2AA02B, \nAGE: 66.946, labtest > cea_labs --> CEA: 1.9000 ng/ml          \nAGE: 66.951, diagnosis > performance_status --> ECOG: 1, \nAGE: 66.993, specimen --> SAMPLE_ID: P-0043580-T01-IM6, \nAGE: 67.234, diagnosis > performance_status --> ECOG: 0, \nAGE: 67.234, labtest > cea_labs --> CEA: 1.3000 ng/ml          \n\n[DrugBank: Veal: Veal allergenic extract is used in allergenic testing.\nDate: Date allergenic extract is used in allergenic testing.\n]\n[FILE: specimen.txt] included in your context\n{\"SAMPLE_ID\": \"P-0043580-T01-IM6\", \"PATIENT_ID\": \"P-0043580\", \"CANCER_TYPE\": \"Colorectal Cancer\", \"SAMPLE_TYPE\": \"Primary\", \"SAMPLE_CLASS\": \"Tumor\", \"METASTATIC_SITE\": \"Not Applicable\", \"PRIMARY_SITE\": \"Ascending Colon\", \"CANCER_TYPE_DETAILED\": \"Colon Adenocarcinoma\", \"GENE_PANEL\": \"IMPACT468\", \"SAMPLE_COVERAGE\": 514, \"TUMOR_PURITY\": 50.0, \"ONCOTREE_CODE\": \"COAD\", \"MSI_COMMENT\": \"MICROSATELLITE STABLE (MSS). See MSI note below.\", \"MSI_SCORE\": 0.0, \"MSI_TYPE\": \"Stable\", \"SOMATIC_STATUS\": \"Matched\", \"CLINICAL_GROUP_x\": \"3A\", \"PATHOLOGICAL_GROUP\": 2.0, \"CLINICAL_SUMMARY\": \"Localized\", \"ICD_O_HISTOLOGY_DESCRIPTION\": \"Mucinous Adenocarcinoma\", \"DIAGNOSIS_DESCRIPTION\": \"Transverse Colon\", \"TMB_NONSYNONYMOUS\": 14.69986761, \"DX_DESCRIPTION\": \"MUCINOUS ADENOCARCINOMA\", \"START_AGE\": 66.8144, \"EVENT_TYPE\": \"Diagnosis\", \"SUBTYPE\": \"Primary\", \"SOURCE\": \"Tumor Registry\", \"CLINICAL_GROUP_y\": \"3A\", \"PATH_GROUP\": \"2A\", \"STAGE_CDM_DERIVED\": \"Stage 1-3\", \"SUMMARY\": \"Localized                                         \", \"ICD_10\": \"C18.4\"}\n"
      },
      {
        "role": "assistant",
        "content": "Okay, I have reviewed both the `timeline0.txt` and `specimen.txt` files. Here's my analysis to determine the likelihood of recurrence within the next 12 months:\n\n**Key Findings from the Timeline:**\n\n*   **Diagnosis & Initial Treatment:** The patient was diagnosed with mucinous adenocarcinoma of the ascending colon at age 66.4. Initial staging was localized (Stage 1-3, Clinical Group 3A, Pathological Group 2A). Surgery was performed.\n*   **CT Scans:** CT scans at ages 66.4 and 66.8 revealed no cancer progression.\n*   **CEA Levels:** CEA levels have been monitored: 10.0 ng/mL, 1.9 ng/mL, and 1.3 ng/mL. The decreasing trend is generally favorable.\n*   **Performance Status:** The patient's ECOG performance status has fluctuated between 0, 1, and 4, but has recently stabilized at 0.\n*   **MSI Status:** The tumor is microsatellite stable (MSS).\n\n**Key Findings from the Specimen Data:**\n\n*   **Cancer Type:** Colon Adenocarcinoma, specifically mucinous adenocarcinoma.\n*   **Primary Site:** Ascending Colon\n*   **TMB:** Tumor Mutational Burden (TMB) is 14.69986761.\n*   **MSI Status:** Confirmed as MSS.\n\n**Assessment of Recurrence Risk:**\n\nGiven the information, here's my reasoning:\n\n*   **Localized Disease & Initial Response:** The initial diagnosis was localized, and the patient responded well to surgery with no evidence of progression on CT scans.\n*   **Decreasing CEA:** The decreasing CEA levels are a positive sign, suggesting a reduced tumor burden or effective treatment.\n*   **MSS Status:** MSS tumors generally have a slightly higher risk of recurrence compared to MSI-high tumors, but this is not a definitive predictor.\n*   **TMB:** A TMB of 14.7 is within a moderate range. It doesn't strongly suggest a high or low risk of recurrence on its own.\n*   **Age:** The patient's age (67.3) is a factor to consider, as older patients may have a slightly higher risk of recurrence.\n*   **ECOG:** The patient's ECOG score of 0 indicates a good performance status, which is a positive prognostic factor.\n\nConsidering all these factors, while recurrence is always a possibility with colon cancer, the current data suggests a relatively low risk of recurrence within the next 12 months. The patient's good response to initial treatment, decreasing CEA levels, and stable performance status are encouraging.\n\n[ANSWER: B) No]"
      },
      {
        "role": "user",
        "content": "\n Question: Given that the patient is 67.3 years old, will the cancer progress in the next 12 months?\nA) Yes\nB) No\nRemember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history.\nExample: [PUBMED: search words]\n"
      },
      {
        "role": "assistant",
        "content": "Okay, I need to assess the likelihood of cancer progression within the next 12 months, considering the patient's current status. I will use the information from the previously reviewed files (`timeline0.txt` and `specimen.txt`).\n\n**Key Points from Previous Analysis:**\n\n*   The patient was initially diagnosed with localized, mucinous colon adenocarcinoma.\n*   CT scans at ages 66.4 and 66.8 showed no evidence of progression.\n*   CEA levels have been decreasing.\n*   The tumor is microsatellite stable (MSS).\n*   The patient's performance status is currently ECOG 0.\n\n**Assessment of Progression Risk:**\n\nGiven the available data, the risk of cancer progression in the next 12 months appears to be relatively low. Here's my reasoning:\n\n*   **Lack of Progression on Recent Imaging:** The most recent CT scans (at ages 66.4 and 66.8) showed no evidence of progression. This is a very important factor.\n*   **Decreasing CEA:** The decreasing CEA levels suggest that the cancer is not actively progressing and may even be responding to treatment or surveillance.\n*   **Good Performance Status:** An ECOG performance status of 0 indicates that the patient is in relatively good health and able to tolerate any necessary treatment or monitoring.\n*   **MSS Status:** While MSS tumors can recur, they don't typically progress rapidly.\n\nAlthough it's impossible to definitively rule out progression, the current data strongly suggests that it is unlikely within the next 12 months.\n\n[ANSWER: B) No]"
      },
      {
        "role": "user",
        "content": "You are given the following new patient information: \nThe patient has no evidence of cancer recurrence or progression within the past 12 months. A detailed history, including diagnosis, treatments, and relevant lab tests, is available for the period between the ages of 67.3 and 69 years, providing valuable insights into the patient\u2019s clinical course and management.\nNew files available:\n [FILE: timeline1.txt]\n[FILE: specimen.txt]\n[FILE: timeline0.txt]Remember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history. If you ask for information, you must wait for the tool to provide it before continuing.\nExample: [PUBMED: search words]\n\n Question: Given that the patient is 69 years old, will the cancer have a recurrence in the next 6 months?\nA) Yes\nB) No\nRemember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history.\nExample: [PUBMED: search words]\n"
      },
      {
        "role": "assistant",
        "content": "Okay, I need to assess the likelihood of cancer recurrence within the next 6 months, considering the new information and the provided files. I will review the new file `timeline1.txt` along with the previously reviewed `timeline0.txt` and `specimen.txt`.\n\n[REQUEST: timeline1.txt]"
      },
      {
        "role": "user",
        "content": "[FILE: timeline1.txt] included in your context\nAGE: 67.483, diagnosis > cancer_presence --> HAS CANCER: No, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: No, PROCEDURE_TYPE: CT scan, PELVIS: Yes, OTHER: No, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 67.483, diagnosis > progression --> CT scan reveals cancer has NOT progressed.\nAGE: 67.483, labtest > cea_labs --> CEA: 1.1000 ng/ml          \nAGE: 67.740, labtest > cea_labs --> CEA: 1.2000 ng/ml          \nAGE: 67.929, surgery --> SUBTYPE: PROCEDURE, \nAGE: 68.250, labtest > cea_labs --> CEA: 1.1000 ng/ml          \nAGE: 68.253, diagnosis > performance_status --> ECOG: 1, \nAGE: 68.497, diagnosis > cancer_presence --> HAS CANCER: No, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: No, PROCEDURE_TYPE: CT scan, PELVIS: Yes, OTHER: No, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 68.497, diagnosis > progression --> CT scan reveals cancer has NOT progressed.\nAGE: 68.497, labtest > cea_labs --> CEA: 0.9000 ng/ml          \nAGE: 68.502, diagnosis > performance_status --> ECOG: 0, \nAGE: 68.749, labtest > cea_labs --> CEA: 1.5000 ng/ml          \nAGE: 68.979, labtest > cea_labs --> CEA: 4.0000 ng/ml          \n\n[DrugBank: Veal: Veal allergenic extract is used in allergenic testing.\n]\n"
      },
      {
        "role": "assistant",
        "content": "Okay, I have reviewed `timeline1.txt`, `timeline0.txt`, and `specimen.txt`. Let's analyze the data to assess the risk of recurrence within the next 6 months.\n\n**Summary of Key Information:**\n\n*   **Previous History (from timeline0.txt & specimen.txt):** Initial diagnosis of mucinous adenocarcinoma (Stage 1-3, MSS), localized disease, surgery performed, initially decreasing CEA levels, good performance status.\n*   **Timeline 1 (67.3 - 69 years):**\n    *   Regular CT scans showing no progression.\n    *   CEA levels fluctuate: 1.1, 1.2, 1.1, 0.9, 1.5, and 4.0 ng/mL. The most recent CEA level (4.0 ng/mL) is significantly elevated compared to previous values.\n    *   Performance status fluctuates between ECOG 1 and 0.\n\n**Assessment of Recurrence Risk:**\n\nThe fluctuating CEA levels, particularly the recent spike to 4.0 ng/mL, are concerning. While CEA can fluctuate for various reasons, a significant increase like this raises the possibility of recurrence or progression. The fact that the patient has been cancer-free for the past 12 months makes this increase even more noteworthy.\n\nAlthough the CT scans have consistently shown no evidence of progression, CEA levels can sometimes rise before structural changes are detectable on imaging.\n\nGiven the recent increase in CEA, I believe the risk of recurrence within the next 6 months is elevated compared to the previous assessment. Further investigation (repeat CT scan, possibly PET scan) is warranted to rule out recurrence.\n\n[ANSWER: A) Yes]"
      },
      {
        "role": "user",
        "content": "\n Question: Given that the patient is 69 years old, will the cancer progress in the next 6 months?\nA) Yes\nB) No\nRemember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history.\nExample: [PUBMED: search words]\n"
      },
      {
        "role": "assistant",
        "content": "Okay, I need to assess the likelihood of cancer progression within the next 6 months, considering the new information and the provided files. The key factor influencing this assessment is the recent, significant increase in CEA levels.\n\n**Recap of Relevant Information:**\n\n*   **Previous History:** Initial localized disease, surgery, initially decreasing CEA.\n*   **Timeline 1 (67.3 - 69 years):** Consistent CT scans showing no progression, but fluctuating CEA levels culminating in a recent value of 4.0 ng/mL.\n\n**Assessment of Progression Risk:**\n\nThe recent rise in CEA to 4.0 ng/mL is the most concerning finding. While CEA can be influenced by factors other than cancer progression, a significant increase like this warrants serious concern. It suggests that the cancer may be reactivating, growing, or metastasizing, even if it's not yet visible on CT scans.\n\nGiven the lack of progression on recent CT scans, it's *possible* that the elevated CEA is due to a non-cancerous cause. However, the prudent approach is to assume that progression is possible and to investigate further.\n\nTherefore, based on the available data, I believe there is a reasonable possibility of cancer progression within the next 6 months. Further investigation with repeat imaging and potentially other diagnostic tests is crucial.\n\n[ANSWER: A) Yes]"
      },
      {
        "role": "user",
        "content": "\n Question: Given that the patient is 69 years old, will the patient be still alive in the next 6 months?\nA) Yes\nB) No\nRemember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history.\nExample: [PUBMED: search words]\n"
      },
      {
        "role": "assistant",
        "content": "Okay, I need to assess the likelihood of the patient being alive in the next 6 months, considering all available information. This is a complex question that requires integrating clinical data with prognostic factors.\n\n**Summary of Key Information:**\n\n*   **Age:** 69 years old.\n*   **Initial Diagnosis:** Mucinous adenocarcinoma, localized disease (Stage 1-3), microsatellite stable (MSS).\n*   **Treatment History:** Surgery performed.\n*   **Recent Findings:** No progression on CT scans, but a concerning increase in CEA levels to 4.0 ng/mL. Performance status fluctuates between ECOG 1 and 0.\n*   **No evidence of recurrence or progression within the past 12 months prior to the recent CEA spike.**\n\n**Assessment of Survival Probability:**\n\nPredicting survival is inherently uncertain, but I can provide an informed assessment based on the available data.\n\n*   **Positive Factors:** The patient initially responded well to treatment, with no evidence of progression for a year. Their performance status is generally good (ECOG 0), indicating they are reasonably functional.\n*   **Negative Factors:** The recent, significant increase in CEA is concerning and suggests a potential for recurrence or progression. While CT scans are currently negative, the CEA elevation warrants further investigation and raises the possibility of disease activity. The patient's age (69) is also a factor, as older individuals may be more vulnerable to complications.\n\nGiven the concerning CEA trend, the possibility of cancer progression exists. If progression occurs, it could negatively impact survival. However, it's also possible that the CEA elevation is due to a non-cancerous cause or that the cancer is slow-growing and manageable.\n\nWithout further information (e.g., results of repeat imaging, response to any potential treatment), it's difficult to provide a definitive answer. However, considering the concerning CEA trend, I must err on the side of caution.\n\n[ANSWER: A) Yes]"
      },
      {
        "role": "user",
        "content": "You are given the following new patient information: \nThe patient has experienced both recurrence and progression of cancer within the past six months. A sample from the patient has been sequenced, and mutation data is available for review. Additionally, a comprehensive medical history, including details of the cancer diagnosis, treatments, and laboratory tests conducted between the ages of 69 and 69.9, is accessible for further evaluation.\nNew files available:\n [FILE: timeline1.txt]\n[FILE: timeline2.txt]\n[FILE: specimen.txt]\n[FILE: timeline0.txt]Remember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history. If you ask for information, you must wait for the tool to provide it before continuing.\nExample: [PUBMED: search words]\n\n Question: Given that the patient is 69.9 years old, will the cancer progress in the next 6 months?\nA) Yes\nB) No\nRemember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history.\nExample: [PUBMED: search words]\n"
      },
      {
        "role": "assistant",
        "content": "Okay, the situation has significantly changed. The patient now has a confirmed history of recurrence and progression within the last six months. I need to review the new file `timeline2.txt` along with the existing files to assess the likelihood of further progression in the next 6 months.\n\n[REQUEST: timeline2.txt]"
      },
      {
        "role": "user",
        "content": "[FILE: timeline2.txt] included in your context\nAGE: 69.091, labtest > cea_labs --> CEA: 11.0000 ng/ml          \nAGE: 69.097, samples > clinical_sample --> SAMPLE_ID: P-0043580-T02-IM7, PATIENT_ID: P-0043580, CANCER_TYPE: Pancreatic Cancer, SAMPLE_TYPE: Metastasis, SAMPLE_CLASS: Tumor, METASTATIC_SITE: Liver, PRIMARY_SITE: Pancreas, CANCER_TYPE_DETAILED: Pancreatic Adenocarcinoma, GENE_PANEL: IMPACT505, SAMPLE_COVERAGE: 168, TUMOR_PURITY: 30.0, ONCOTREE_CODE: PAAD, MSI_COMMENT: MICROSATELLITE STABLE (MSS). See MSI note below., MSI_SCORE: 0.84, MSI_TYPE: Stable, SOMATIC_STATUS: Matched, CLINICAL_GROUP_x: 4, PATHOLOGICAL_GROUP: 4.0, CLINICAL_SUMMARY: Distant Metastases/Systemic Disease, ICD_O_HISTOLOGY_DESCRIPTION: Adenocarcinoma, Nos, DIAGNOSIS_DESCRIPTION: Pancreas, TMB_NONSYNONYMOUS: 2.46104171, DX_DESCRIPTION: ADENOCARCINOMA, NOS, EVENT_TYPE: Diagnosis, SUBTYPE: Primary, SOURCE: Tumor Registry, CLINICAL_GROUP_y: 4, PATH_GROUP: 4, STAGE_CDM_DERIVED: Stage 4, SUMMARY: Distant metastases/systemic disease, ICD_10: C25.2, \nAGE: 69.097, diagnosis > diagnosis --> SUBTYPE: Primary, SOURCE: Tumor Registry, DX_DESCRIPTION: ADENOCARCINOMA, NOS | PANCREAS, TAIL (M8140/3 | C252), CLINICAL_GROUP: 4, PATH_GROUP: 4, STAGE_CDM_DERIVED: Stage 4, SUMMARY: Distant metastases/systemic disease, \nAGE: 69.097, diagnosis > cancer_presence --> HAS CANCER: Yes, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: Yes, PROCEDURE_TYPE: CT scan, PELVIS: Yes, OTHER: No, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.097, diagnosis > progression --> CT scan reveals cancer has progressed.\nAGE: 69.097, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), CT, TUMOR_SITE: Liver, PELVIS: Yes, OTHER: No, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.118, labtest > cea_labs --> CEA: 12.9000 ng/ml          \nAGE: 69.135, surgery --> SUBTYPE: SAMPLE, \nAGE: 69.135, specimen_surgery --> SAMPLE_ID: P-0043580-T02-IM7, SEQ_DATE: 914, \nAGE: 69.140, diagnosis > cancer_presence --> HAS CANCER: Yes, SUBTYPE: HasCancer, PROCEDURE_TYPE: MR, HAS_CANCER: Yes, PROCEDURE_TYPE: MR, PELVIS: No, OTHER: Yes, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: No, CHEST: No, \nAGE: 69.140, diagnosis > progression --> PROGRESSION: N, PROCEDURE_TYPE: MR, \nAGE: 69.140, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), MR, TUMOR_SITE: Other, PELVIS: No, OTHER: Yes, HEAD: No, ABDOMEN: No, CHEST: No, \nAGE: 69.140, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), MR, TUMOR_SITE: Liver, PELVIS: No, OTHER: Yes, HEAD: No, ABDOMEN: No, CHEST: No, \nAGE: 69.151, diagnosis > performance_status --> ECOG: 0, \nAGE: 69.151, diagnosis > performance_status --> ECOG: 2, \nAGE: 69.151, labtest > ca_19-9_labs --> RESULT: 728, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.179, surgery --> SUBTYPE: SAMPLE, \nAGE: 69.179, surgery --> SUBTYPE: PROCEDURE, \nAGE: 69.198, diagnosis > performance_status --> ECOG: 0, \nAGE: 69.198, diagnosis > performance_status --> ECOG: 2, \nAGE: 69.198, labtest > ca_19-9_labs --> RESULT: 1933, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.198, labtest > cea_labs --> CEA: 30.2000 ng/ml          \nAGE: 69.201, treatment > treatment --> STOP_AGE: 69.6801, SUBTYPE: Chemo, AGENT: OXALIPLATIN, RX_INVESTIGATIVE: N, FLAG_OROTOPICAL: 0, \nAGE: 69.201, treatment > treatment --> STOP_AGE: 69.6801, SUBTYPE: Chemo, AGENT: LEUCOVORIN, RX_INVESTIGATIVE: N, FLAG_OROTOPICAL: 0, \nAGE: 69.201, treatment > treatment --> STOP_AGE: 69.6801, SUBTYPE: Chemo, AGENT: IRINOTECAN, RX_INVESTIGATIVE: N, FLAG_OROTOPICAL: 0, \nAGE: 69.201, treatment > treatment --> STOP_AGE: 69.6801, SUBTYPE: Chemo, AGENT: FLUOROURACIL, RX_INVESTIGATIVE: N, FLAG_OROTOPICAL: 0, \nAGE: 69.275, labtest > ca_19-9_labs --> RESULT: 3870, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.351, labtest > ca_19-9_labs --> RESULT: 2700, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.390, labtest > ca_19-9_labs --> RESULT: 1653, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.466, labtest > ca_19-9_labs --> RESULT: 696, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.486, diagnosis > cancer_presence --> HAS CANCER: Yes, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: Yes, PROCEDURE_TYPE: CT scan, PELVIS: Yes, OTHER: No, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.486, diagnosis > progression --> CT scan reveals cancer has NOT progressed.\nAGE: 69.486, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), CT, TUMOR_SITE: Liver, PELVIS: Yes, OTHER: No, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.497, specimen --> SAMPLE_ID: P-0043580-T02-IM7, \nAGE: 69.497, labtest > ca_19-9_labs --> RESULT: 581, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.582, labtest > ca_19-9_labs --> RESULT: 478, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.677, labtest > ca_19-9_labs --> RESULT: 1692, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.710, diagnosis > cancer_presence --> HAS CANCER: Yes, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: Yes, PROCEDURE_TYPE: CT scan, PELVIS: Yes, OTHER: No, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.710, diagnosis > progression --> CT scan reveals cancer has progressed.\nAGE: 69.710, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), CT, TUMOR_SITE: Liver, PELVIS: Yes, OTHER: No, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.710, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), CT, TUMOR_SITE: Other, PELVIS: Yes, OTHER: No, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.716, labtest > ca_19-9_labs --> RESULT: 2972, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.735, labtest > ca_19-9_labs --> RESULT: 4365, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.749, diagnosis > cancer_presence --> HAS CANCER: Yes, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: Yes, PROCEDURE_TYPE: CT scan, PELVIS: Yes, OTHER: No, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.749, diagnosis > progression --> CT scan reveals cancer has NOT progressed.\nAGE: 69.749, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), CT, TUMOR_SITE: Liver, PELVIS: Yes, OTHER: No, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.749, diagnosis > tumor_sites --> SOURCE: Radiology Reports (NLP), CT, TUMOR_SITE: Other, PELVIS: Yes, OTHER: No, HEAD: No, ABDOMEN: Yes, CHEST: Yes, \nAGE: 69.770, surgery --> SUBTYPE: SAMPLE, \nAGE: 69.773, treatment > treatment --> STOP_AGE: 69.9267, SUBTYPE: Chemo, AGENT: PACLITAXEL PROTEIN-BOUND, RX_INVESTIGATIVE: N, FLAG_OROTOPICAL: 0, \nAGE: 69.773, treatment > treatment --> STOP_AGE: 69.9267, SUBTYPE: Chemo, AGENT: GEMCITABINE, RX_INVESTIGATIVE: N, FLAG_OROTOPICAL: 0, \nAGE: 69.773, diagnosis > performance_status --> ECOG: 1, \nAGE: 69.773, labtest > ca_19-9_labs --> RESULT: 7922, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.809, diagnosis > performance_status --> ECOG: 2, \nAGE: 69.812, diagnosis > cancer_presence --> HAS CANCER: No, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: No, PROCEDURE_TYPE: CT scan, PELVIS: No, OTHER: No, SUBTYPE: HasCancer, HEAD: Yes, ABDOMEN: No, CHEST: No, \nAGE: 69.812, diagnosis > cancer_presence --> HAS CANCER: No, SUBTYPE: HasCancer, PROCEDURE_TYPE: CT, HAS_CANCER: No, PROCEDURE_TYPE: CT scan, PELVIS: No, OTHER: No, SUBTYPE: HasCancer, HEAD: No, ABDOMEN: No, CHEST: Yes, \nAGE: 69.812, diagnosis > progression --> CT scan reveals cancer has NOT progressed.\nAGE: 69.812, diagnosis > progression --> CT scan reveals cancer has NOT progressed.\nAGE: 69.850, diagnosis > performance_status --> ECOG: 1, \nAGE: 69.850, labtest > ca_19-9_labs --> RESULT: 5727, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.869, labtest > ca_19-9_labs --> RESULT: 5811, LR_UNIT_MEASURE: Units/ml, \nAGE: 69.888, labtest > ca_19-9_labs --> RESULT: 4200, LR_UNIT_MEASURE: Units/ml, \n\n[DrugBank: Gemcitabine: Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers.[A233135] Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose.[A233145] As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells.[L32960] The structure, metabolism, and mechanism of action of gemcitabine are similar to [cytarabine], but gemcitabine has a wider spectrum of antitumour activity.[A233140]\r\n\r\nGemcitabine is marketed as Gemzar and it is available as intravenous injection. It is approved by the FDA to treat advanced ovarian cancer in combination with [carboplatin], metastatic breast cancer in combination with [paclitaxel], non-small cell lung cancer in combination with [cisplatin], and pancreatic cancer as monotherapy.[L32950] It is also being investigated in other cancer and tumour types.\nOxaliplatin: Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect.[A797] However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties.[A797] Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics.[A260396] Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking.[A260396] However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects.[A260396] The DACH moiety also prevents cross-resistance with cisplatin and carboplatin.[A797]\r\n\r\nAlthough oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer.[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin\u2019s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer.[A797]\r\n\r\nOxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin&reg;.[L47316]\nFluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.\nLeucovorin: Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the levo-isomer has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form is slowly excreted by the kidneys. Despite this difference in activity, the two commercially available forms have been shown to be pharmacokinetically identical and may be used interchangeably with limited differences in efficacy or side effects (Kovoor et al, 2009). \r\n\r\nAs folate analogs, leucovorin and levoleucovorin are both used to counteract the toxic effects of folic acid antagonists, such as methotrexate, which act by inhibiting the enzyme dihydrofolate reductase (DHFR). They are indicated for use as rescue therapy following use of high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists. Injectable forms are also indicated for use in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible and for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. \r\n\r\nFolic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects associated with methotrexate therapy. As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects.\nIrinotecan: Irinotecan is a topoisomerase inhibitor used for chemotherapy. It is a water-soluble analogue of [camptothecin], which is extracted from the Chinese tree _Camptotheca acuminate_.[A263376] The bis-piperidine side chain in the structure of irinotecan bestows enhanced water solubility.[A263381] As an anticancer drug, irinotecan was first commercially available in Japan in 1994 to treat various cancers such as lung, cervical and ovarian cancer.[A263376] Approved by the FDA in 1996,[A263366] irinotecan is used to treat colorectal cancer and pancreatic adenocarcinoma.[L50181, L50186, L50201] Irinotecan liposome was approved by the FDA in February 2024.[L50186]\r\n\r\nThe active metabolite SN-38 is also a potent inhibitor of DNA topoisomerase I. Both irinotecan and SN-38 mediate antitumor activity by forming a complex with topoisomerase\u2005I and blocking its enzymatic activity, thereby interfering with DNA synthesis. This leads to the arrest of the cell cycle in the S-G2 phase and cancer cell death.[A263376]\nPaclitaxel: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.\nUracil: nan\nVeal: Veal allergenic extract is used in allergenic testing.\nDate: Date allergenic extract is used in allergenic testing.\n]\n"
      },
      {
        "role": "assistant",
        "content": "Okay, I have reviewed `timeline2.txt`, `timeline1.txt`, `timeline0.txt`, and `specimen.txt`. The situation is now very concerning.\n\n**Summary of Key Findings:**\n\n*   **Initial Presentation:** Mucinous adenocarcinoma, localized, Stage 1-3, MSS.\n*   **Timeline 1 (67.3-69 years):** Initial stability, then concerning rise in CEA, fluctuating performance status.\n*   **Timeline 2 (69-69.9 years):**\n    *   **Metastasis:** Confirmed metastasis to the liver.\n    *   **Rapid CEA Increase:** Dramatic increase in CEA from 11.0 to 30.2, then to 7922 ng/mL.\n    *   **CA 19-9 Elevation:** Extremely elevated CA 19-9 levels, reaching 7922 units/mL.\n    *   **Chemotherapy:** Treatment with FOLFOX (Fluorouracil, Leucovorin, Oxaliplatin) and then Paclitaxel/Gemcitabine.\n    *   **Continued Progression:** Despite chemotherapy, CT scans show continued progression.\n    *   **Performance Status Decline:** Performance status has declined to ECOG 2.\n\n**Assessment of Progression Risk:**\n\nGiven the overwhelming evidence of metastasis, rapid disease progression, and minimal response to chemotherapy, the likelihood of further progression in the next 6 months is extremely high. The escalating CEA and CA 19-9 levels are strong indicators of ongoing tumor activity. The patient's declining performance status further supports this assessment.\n\n[ANSWER: A) Yes]"
      },
      {
        "role": "user",
        "content": "\n Question: Given that the patient is 69.9 years old, will the patient be still alive in the next 6 months?\nA) Yes\nB) No\nRemember that you can ask for files by providing the following tag [REQUEST: filename.extension]. You may also ask for multiple files at once if necessary. If you ask for a file, you MUST WAIT to receive it from the user.\nYou must provide a separate [REQUEST] tag for each file you need. Example [REQUEST: image1.jpg] [REQUEST: image2.jpg].\nYou also have access to PUBMED that you can use to query articles that may potentially be relevant to the patient history.\nExample: [PUBMED: search words]\n"
      },
      {
        "role": "assistant",
        "content": "Okay, I need to assess the likelihood of the patient being alive in the next 6 months, given the extremely concerning clinical picture.\n\n**Recap of Critical Information:**\n\n*   **Metastatic Disease:** Confirmed liver metastasis.\n*   **Rapid Progression:** Demonstrated by escalating CEA and CA 19-9 levels despite chemotherapy.\n*   **Chemotherapy Resistance:** Minimal response to multiple chemotherapy regimens (FOLFOX, Paclitaxel/Gemcitabine).\n*   **Declining Performance Status:** ECOG performance status of 2.\n*   **Age:** 69.9 years old.\n\n**Assessment of Survival Probability:**\n\nThe patient's prognosis is now very poor. The presence of widespread metastatic disease, rapid progression despite chemotherapy, and a declining performance status are all strong indicators of a limited life expectancy. While it is impossible to predict the future with certainty, the available data strongly suggests that the patient's survival is likely to be measured in months, rather than years.\n\nGiven the aggressive nature of the disease and the lack of a positive response to treatment, I must conclude that the likelihood of the patient being alive in 6 months is low.\n\n[ANSWER: B) No]"
      }
    ]
  }
]